LongBio Pharma's Allergic Rhinitis Drug Application Accepted in China
MT Newswires Live
Aug 21
LongBio Pharma (Suzhou)'s (HKG:1779) biologics license application for LP-003 was accepted by China's National Medical Products Administration.
The acceptance is for the indication of seasonal allergic rhinitis, according to a Friday Hong Kong bourse filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.